Menu

Smallest Cas9 Ortholog Reported

Researchers demonstrate the delivery of AAV-packaged CRISPR-CjCas9 into the muscles and eyes of mice.

Feb 23, 2017
Tracy Vence

Comparison of Cas9 “gene scissors” from different bacteria: Streptococcus pyogenes, Staphylococcus aureus, and Campylobacter jejuni.INSTITUTE FOR BASIC SCIENCEAn ortholog to Streptococcus pyogenes Cas9 (SpCas9), Campylobacter jejuni Cas9 (CjCas9) is composed of just 984 amino-acid residues, making it the smallest such RNA-guided endonuclease characterized to date, according to researchers at the Institute for Basic Science in Seoul, who published their findings in Nature Communications this week (February 22).

The researchers packaged CRISPR-CjCas9 into an adeno-associated viral (AAV) vector, which they then injected into the muscles and eyes of mice. To demonstrate CjCas9’s capabilities, they used the system to modify a mouse gene linked to blindness. “CjCas9 is highly specific and does not cause off-target mutations in the genome,” coauthor Jin-Soo Kim of the Institute for Basic Science said in a statement.

“The researchers noted that CjCas9 designed to target six different DNA regions cleaved between one and 27 sites in the human and mouse genomes, suggesting that it is specific,” GenomeWeb reported. “By comparison, SpCas9”—made up of 1,368 amino acids and derived from Streptococcus pyogenes—“cleaved some 15 to 147 sites.”

The specificity of CjCas9could have clinical implications, the authors wrote. In their paper, Kim and colleagues proposed that “in vivo genome editing with CjCas9 is a new option for the treatment of age-related macular degeneration.”

See “New CRISPR-Cas Enzymes Discovered

See “Cas9 Further Refined

See “A CRISPR Fore-Cas-t

See “CRISPR 2.0?

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.

Thermo Fisher Scientific: Freezers for Biological Samples

Thermo Fisher Scientific: Freezers for Biological Samples

Fluctuations in temperature can reduce the efficacy, decompose, or shorten the shelf life of biologics. Therefore, it is important to store biologics at the right temperature using standardized protocols.